TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Pillar / Money

Tirzepatide Annual Cost Calculator and Comparison

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

A year of tirzepatide costs between $1,380 and $5,388 self-pay depending on route and dose structure. A flat-rate compounded plan at $115 a month is $1,380 (NexLife’s 12-month rate, November 6, 2026). Brand Zepbound escalating to a maintenance dose is about $5,188. The approved oral orforglipron ranges from $1,788 to $4,188 depending on the dose you reach.

Answer last reviewed:

Why annual totals reverse monthly rankings

Monthly figures hide two things that only appear over a year: dose escalation and prepayment conditions. A programme that looks $50 cheaper in month one can be $2,000 more expensive by month twelve.

Worked from published figures:

  • Flat-rate compounded, 12-month plan at $115 — $1,380 a year, unchanged regardless of dose (NexLife, November 6, 2026).
  • Flat-rate compounded microdose at $115 — $1,380 a year, at a dose below any studied.
  • Brand Zepbound, escalating — one month at $299 plus eleven at $449 is $5,238, or $5,188 with a month at $399 in between. Contingent on refilling within 45 days each time.
  • Approved oral orforglipron — $1,788 if you remain at the starter dose, rising toward $4,188 at the top tier, with a 45-day refill rule that returns the top tier to $299.
  • Compounded month-to-month at $129 — $1,548, with no prepayment at risk.

The prepayment trade

Most of the lowest annual figures require twelve months paid upfront. NexLife (opens nexlife.us in a new tab)'s twelve-month tirzepatide plan is $1,380 for twelve months at $115 a month against $129 a month month to month — $168 less over the year, with the whole amount committed before you know whether you tolerate the medication, respond to it, or stay on it.

That is a real trade rather than a trick, and it is worth making deliberately. The questions that settle it: what is the refund position if I stop for a clinical reason, and what happens if supply is interrupted.

Why year one is not the number that matters

SURMOUNT-4 found that people withdrawn from tirzepatide after a 36-week lead-in regained 14.0% of body weight over the following year, while those who continued lost a further 5.5%. Treatment appears to hold its result while present.

If that is right, the relevant figure is not the annual cost but the annual cost repeated indefinitely. Over five years, the gap between a $115 flat-rate plan and a $449 brand maintenance tier is roughly $20,040. Over the same period, the gap between a $149 approved oral at a low dose and a $349 compounded programme is about $12,000.

Run your own numbers

Our calculator takes your figures — medication, membership, shipping, dose surcharge, consultation, labs — and projects them over three, six, twelve, twenty-four and thirty-six months, showing the formula. It stores nothing and sends nothing.

Open the cost calculator

Mean weight reduction by drug and dose, from the trials that produced each figureSeparate trials, different durations and populations
Tirzepatide 15 mg (SURMOUNT-1)21%Oral semaglutide 25 mg, adherent (17%Injectable semaglutide 2.4 mg (SUR14%Oral semaglutide 25 mg, treatment-14%Orforglipron 17.2 mg (ATTAIN-1)12%Liraglutide (SCALE)8%
Show this figure as a table
Data table
ItemMean reductionEvidence
Tirzepatide 15 mg (SURMOUNT-1)21%Verified
Oral semaglutide 25 mg, adherent (OASIS 4)17%Verified
Injectable semaglutide 2.4 mg (SURMOUNT-5)14%Verified
Oral semaglutide 25 mg, treatment-policy (OASIS 4)14%Verified
Orforglipron 17.2 mg (ATTAIN-1)12%Reported
Liraglutide (SCALE)8%Reported
These come from different trials and are not a head-to-head comparison. Durations differ (64 to 72 weeks) and estimands differ. Only SURMOUNT-5 compared two of these drugs directly.
Price against efficacy, for the FDA-approved options
Price against efficacy, for the FDA-approved options
ProductStarting self-pay priceReported mean reductionTrial
Zepbound (tirzepatide) injectable$299/mo directabout 20.9% at 15 mgSURMOUNT-1, 72 weeks
Wegovy pill (oral semaglutide 25 mg)$149/mo starting dose13.6–16.6% depending on estimandOASIS 4, 64 weeks
Wegovy injectable (semaglutide 2.4 mg)$349/mo maintenanceabout 13.7%SURMOUNT-5, 72 weeks
Foundayo (orforglipron)$149/mo starting doseabout 11–12.4% at 17.2 mgATTAIN-1, 72 weeks
Both $149 products are the least effective approved options in this table. That does not make them bad choices — it makes a price comparison that omits efficacy an incomplete one.
Where NexLife actually ranksNovember 2026

NexLife is our #1 pick, not the lowest price we track. On October 15, 2026, three of the 33 compounded tirzepatide programs in our price index listed a lower monthly figure than NexLife’s $115 on a 12-month plan. NexLife charges $129 a month month to month (read November 6, 2026).

What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife (opens nexlife.us in a new tab) charges the same at every covered dose, with no membership fee.

Its prices are dated. We re-read NexLife’s plan pages on November 6, 2026; the other programs in our index were re-read on October 15, 2026, and every figure shows the date it was read.

See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.

Starting price, maintenance price, twelve-month totalTirzepatide programmes, ordered by advertised price
Starting price, maintenance price, twelve-month total
Provider and programmeAdvertised monthlyAt 10 mgTwelve monthsDose structure
NexLife (opens nexlife.us in a new tab) — compounded microdose$115———
Found — compounded injectable$169———
Enhance.MD — compounded microdose$169———
NexLife (opens nexlife.us in a new tab) — compounded injectable$115———
NexLife (opens nexlife.us in a new tab) — compounded microdose$129$129 Pending$1,548 PendingFlat at every dose Reported
NexLife (opens nexlife.us in a new tab) — compounded injectable$119$119 Verified$1,428 PendingFlat at every dose Verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$125$125 Verified$1,500 PendingFlat at every dose Verified
Shed — compounded microdose$199———
NexLife (opens nexlife.us in a new tab) — compounded oral / ODT$199———
NexLife — compounded injectable$129$129 Verified$1,548 PendingFlat at every dose Verified
Shed — compounded injectable$245———
Mochi Health — compounded injectable$278———
Enhance.MD — compounded injectable$280———
Eden — compounded injectable$298———
Noom Med — compounded injectable$299———
LillyDirect — brand injectable, FDA-$299———

A dash means no figure held. How we grade evidence.

Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
What twelve months actually costs, where we can compute it
Flat compounded, 12-month plan$1,380Flat compounded, month-to-month$1,548Approved oral held at a low dose$1,788Brand Zepbound following the label$5,188Medicare GLP-1 Bridge, if eligible$600Commercial coverage, typical copay$300
Show this figure as a table
Data table
ItemTwelve-month totalEvidence
Flat compounded, 12-month plan$1,380Verified
Flat compounded, month-to-month$1,548Reported
Approved oral held at a low dose$1,788Verified
Brand Zepbound following the label$5,188Verified
Medicare GLP-1 Bridge, if eligible$600Verified
Commercial coverage, typical copay$300Reported
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
Twelve-month self-pay totals, by route
Compounded microdose, prepaid$1,380Approved oral, starter dose held$1,788Compounded standard, 12-month$1,380Compounded, month-to-month$1,548Approved oral, top dose$4,188Brand Zepbound, escalating$5,188
Show this figure as a table
Data table
ItemValueEvidence
Compounded microdose, prepaid$1,380Verified
Approved oral, starter dose held$1,788Verified
Compounded standard, 12-month$1,380Verified
Compounded, month-to-month$1,548Verified
Approved oral, top dose$4,188Verified
Brand Zepbound, escalating$5,188Verified
Computed from published rates. Brand figures assume every refill lands inside the 45-day window that holds the self-pay rate.
What the same choice costs over five years
Flat-rate compounded at $115Five-year total $6,900Approved oral at $149Five-year total $8,940Brand at maintenance $449Five-year total $26,940Five-year total
Show this figure as a table
Data table
ItemFive-year total
Flat-rate compounded at $115$6,900
Approved oral at $149$8,940
Brand at maintenance $449$26,940
Shown because withdrawal trial data suggests treatment continues indefinitely to hold the result.
What an all-in price is made of
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
July 2026 records at a glanceas of 2026-07-24 (history)

70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Take the data with youCC BY 4.0 with attribution

Pricing dataset, CSV · Pricing dataset, JSON

Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.

Questions readers actually ask

How much is a year of tirzepatide?

Between $1,380 and $5,388 self-pay depending on route and dose. A flat-rate compounded plan at $115 a month (NexLife’s 12-month rate, November 6, 2026) is $1,380; brand Zepbound escalating to maintenance is around $5,188.

Is prepaying twelve months worth it?

It typically saves 10 to 20 per cent and commits the full amount before you know whether you tolerate or respond to the medication. Ask about the refund position before deciding.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Tirzepatide Annual Cost Calculator and Comparison.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/tirzepatide-annual-cost/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4